Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...

Amgen investors have been focused on prospects for MariTide, which activates the appetite- and blood sugar-reducing hormone ...

Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...

Amgen’s mysterious obesity asset will remain a mystery for a bit longer—the FDA has put the candidate’s phase 1 trial ...

Amgen Inc (NASDAQ:AMGN)., a leading biopharmaceutical company with a market capitalization of $155 billion, is at a pivotal juncture as it navigates the competitive landscape of innovative ...

Amgen reported strong fourth-quarter earnings, driven by strategic acquisitions and robust product sales growth.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

The company said the agency's hold was "not related to the drug,” dubbed AMG 513, and that discussions were underway to ...

Amgen (AMGN) provided updates on selected product and pipeline programs, including that a Phase 1 study of AMG 513 in people living with ...

Amgen Inc . (NASDAQ:AMGN), a leading biotechnology company with a market capitalization of $151.3 billion, is navigating a ...

Amgen Inc.’s disclosed that US regulators paused the study of an early-stage obesity drug, a lucrative market the company is ...

Q4 2024 . Management View. Amgen highlighted its robust performance in 2024, achieving 14 products annualizing over $1 billion in ...